For the estimation of immunotherapy, we also found that in the group of AHCYL1 deletion, patients had higher TIDE values, indicating higher potential of tumor immune evasion (Figure 2(c)), and were less likely to benefit from immunotherapy (Figure 2(d)). This evidence concerns the gene AHCYL1 and neoplasm.